= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CELL LINE LICENSE AGREEMENTCell Line License Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations
This Cell Line License Agreement (“Agreement”), effective as of June 20, 2022 (“Effective Date”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Paragon Therapeutics, Inc., a Delaware corporation, with an office at 34 Cypress Rd., Arlington, MA 02474 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
CELL LINE LICENSE AGREEMENTCell Line License Agreement • November 10th, 2020 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • New York
This Cell Line License Agreement (“Agreement”), effective as of 11 October 2019 (“EFFECTIVE DATE”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Silverback Therapeutics, Inc., having its principal place of business at 500Fairview Ave. N #600, Seattle, WA 98109 (“Licensee”). WuXi Biologics and Licensee may bereferred to herein individually as a “Party” and collectively as the “Parties.”
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CELL LINE LICENSE AGREEMENTCell Line License Agreement • June 22nd, 2023 • Apogee Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Cell Line License Agreement (“Agreement”), effective as of June 20, 2022 (“Effective Date”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Paragon Therapeutics, Inc., a Delaware corporation, with an office at 34 Cypress Rd., Arlington, MA 02474 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
CELL LINE LICENSE AGREEMENTCell Line License Agreement • May 19th, 2021 • Janux Therapeutics, Inc. • Pharmaceutical preparations
This Cell Line License Agreement (“Agreement”), effective as of April 19, 2021 (“EFFECTIVE DATE”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Janux Therapeutics, Inc., having its principal place of business at 11099 N. Torrey Pines Road, La Jolla, California 92037, USA. WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties”.
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CELL LINE LICENSE AGREEMENTCell Line License Agreement • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations
This Cell Line License Agreement (“Agreement”), effective as of October 22, 2024 (“EFFECTIVE DATE”), is entered and made by and between WuXi Biologics Ireland Limited, having an address at Dundalk Science & Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (collectively, “WuXi Biologics”) and Jade BioSciences, Inc., a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
LIFE TECHNOLOGIES CELL LINE LICENSE AGREEMENTCell Line License Agreement • May 16th, 2019 • BridgeBio Pharma LLC • Pharmaceutical preparations • California
This Cell Line License Agreement (the “Agreement” or the “License”), effective as of November 15, 2018 (the “Effective Date”), by and between Life Technologies Corporation, a Delaware corporation having its principal place of business at 5781 Van Allen Way, Carlsbad, CA 92008 USA (“Life”), and BridgeBio Services, Inc., a Delaware Limited Liability Company having its principal place of business at 421 Kipling Street, Palo Alto, California 94301, USA (“Licensee”). Each of Life and Licensee may be referred to herein as a “Party” and collectively as the “Parties”.
CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 2 TO CELL LINE LICENSE AGREEMENTCell Line License Agreement • August 11th, 2022 • Silverback Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment”) is entered into between Silverback Therapeutics, Inc. (“Licensee”) and WuXi Biologics (Hong Kong) Limited (“WuXi Biologics”), effective as of the date of the last signature hereto, and amends, as set forth herein, the Cell Line License Agreement (the “CLLA”), effective as of 11 October, 2019 entered into between Licensee and WuXi Biologics. Each of WuXi Biologics and Licensee are referred to from time to time as a “Party” and collectively as the “Parties”. All terms used but not otherwise defined in this Amendment shall have the meanings accorded to them in the CLLA.
Cell Line License AgreementCell Line License Agreement • March 24th, 2022
foteonsemOabrlaedsi aliubnadcekswphaecnedpevrecruyrrgeennteSroaunsdly dwahmileesHvaamrilednlyreamnadincsroMssu-hfearmtilmiziandgahnearncdarfduisnilael-.pLreiensnt.ie reoshtiibtuittieonWisetsidraercsktliellswsliyn.drows: faithful and bossiest Wallie consort quite earlier but remigrated her
AMENDMENT NO. 2 TO THE CELL LINE LICENSE AGREEMENTCell Line License Agreement • March 28th, 2024 • Invivyd, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 2 TO THE CELL LINE LICENSE AGREEMENT (this “Amendment No. 2”), effective as of March 13, 2024 (“the Amendment No. 2 Effective Date”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”), and Invivyd, Inc. having its principal place of business at 1601 Trapelo Road, Suite 178, Waltham, MA 02451 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO CELL LINE LICENSE AGREEMENTCell Line License Agreement • March 29th, 2021 • Silverback Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) is entered into between Silverback Therapeutics, Inc. (“Licensee”) and WuXi Biologics (Hong Kong) Limited (“WuXi Biologics”), effective as of the date of the last signature hereto, and amends, as set forth herein, the Cell Line License Agreement (the “CLLA”), effective as of 11 October, 2019 entered into between Licensee and WuXi Biologics. Each of WuXi Biologics and Licensee are referred to from time to time as a “Party” and collectively as the “Parties”. All terms used, but not otherwise defined, in this Amendment shall have the meanings accorded to them in the CLLA.
LIFE TECHNOLOGIES [***] CELL LINE LICENSE AGREEMENTCell Line License Agreement • November 13th, 2020 • BioAtla, Inc. • Biological products, (no disgnostic substances) • California
This [***] CELL LINE LICENSE AGREEMENT (the “AGREEMENT”), is entered Into and made effective as of June 28 2018 (the “EFFECTIVE DATE”), by and between Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific Inc., having its principal place of business at 5823 Newton Drive, Carlsbad, CA 92008 USA (“LIFE”), and the following organization, organized under the laws of the indicated state or jurisdiction, and having its principal place of business at the indicated address as follows:
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED CELL LINE...Cell Line License Agreement • October 15th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations
This Amended and Restated Cell Line License Agreement (“Agreement”), effective as of the latest date of signature (the “Effective Date”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Spyre Therapeutics, Inc., a Delaware corporation, with an office at 221 Crescent Street, Building 17, Suite 102B, Waltham, MA 02453 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENTCell Line License Agreement • March 23rd, 2023 • Invivyd, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT (this “Amendment”), effective as of February 2, 2023 (“the Amendment Effective Date”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”), and Invivyd, Inc. having its principal place of business at 1601 Trapelo Road, Suite 178, Waltham, MA 02451 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LIFE TECHNOLOGIES CELL...Cell Line License Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • California
This CELL LINE LICENSE AGREEMENT (the “AGREEMENT” or the “LICENSE”), effective as of November 20, 2016 (the “EFFECTIVE DATE”), by and between Life Technologies Corporation, a Delaware corporation having its principal place of business at 5781 Van Allen Way, Carlsbad, CA 92008 USA (“LICENSOR”), and Solid Biosciences, a Delaware limited liability company having its principal place of business at 161 Third Street, Third Floor, Cambridge, MA 02142 (“LICENSEE”). Each of LICENSOR and LICENSEE may be referred to herein as a “PARTY” and collectively as the “PARTIES”.
CELL LINE LICENSE AGREEMENTCell Line License Agreement • July 16th, 2021 • Adagio Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Cell Line License Agreement (“Agreement”), effective as of December 2, 2020 (“Effective Date”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Adagio Therapeutics, Inc., having an address at 303 Wyman Street, Suite 300, Waltham, MA 02451 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
LIFE TECHNOLOGIES CELL LINE LICENSE AGREEMENTCell Line License Agreement • January 16th, 2018 • Solid Biosciences, LLC • Biological products, (no disgnostic substances) • California
This CELL LINE LICENSE AGREEMENT (the “AGREEMENT” or the “LICENSE”), effective as of November 20, 2016 (the “EFFECTIVE DATE”), by and between Life Technologies Corporation, a Delaware corporation having its principal place of business at 5781 Van Allen Way, Carlsbad, CA 92008 USA (“LICENSOR”), and Solid Biosciences, a Delaware limited liability company having its principal place of business at 161 Third Street, Third Floor, Cambridge, MA 02142 (“LICENSEE”). Each of LICENSOR and LICENSEE may be referred to herein as a “PARTY” and collectively as the “PARTIES”.
